Figure 1.
Correlations between nonbodyweight‐corrected tacrolimus (Tac) apparent oral clearance (Cl/F) and 4β‐hydroxycholesterol/cholesterol (4β‐OHC/C) (A), weight‐corrected Tac Cl/F/W and 4β‐OHC/C/W (B), Tac Cl/F and midazolam (MDZ) Cl/F (C) as well as between bodyweight and Tac Cl/F (D), 4β‐OHC/C (E) and MDZ Cl/F (F)